AR109562A1 - Compuestos de indazol como antagonistas de crth2 - Google Patents
Compuestos de indazol como antagonistas de crth2Info
- Publication number
- AR109562A1 AR109562A1 ARP170102438A ARP170102438A AR109562A1 AR 109562 A1 AR109562 A1 AR 109562A1 AR P170102438 A ARP170102438 A AR P170102438A AR P170102438 A ARP170102438 A AR P170102438A AR 109562 A1 AR109562 A1 AR 109562A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- 6alkyl
- heterocycloalkyl
- coo
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- -1 - O-aryl Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos indazolo sustituidos, sus sales farmacéuticamente aceptables y sus isómeros, esteroisómeros, atropisómeros, confórmeros, tautómeros, polimorfos, hidratos o solvatos. También comprende composiciones farmacéuticamente aceptables de los mencionados compuestos y el proceso para preparar compuestos. Asimismo se relaciona con el uso de los compuestos arriba mencionados para la preparación de un medicamento para uso como producto farmacéutico. Reivindicación 1: Un compuesto de la fórmula (1), donde, n se selecciona independientemente de 1, 2 y 3; m se selecciona de 0 - 2; Y es -OZ; Z se selecciona de H y un catión; R y R’ se seleccionan independientemente de hidrógeno y C₁₋₃alquilo; R¹ se selecciona de C₁₋₆alquilo y C₃₋₈cicloalquilo; R² se selecciona independientemente de hidrógeno, C₁₋₆alquilo, C₂₋₆alquenilo, C₂₋₆alquinilo, arilo, heteroarilo, heterocicloalquilo, halo, -NO₂, hidroxilo, CF₃, C₁₋₆alcoxi, -S-C₁₋₆alquilo, -SO₂-C₁₋₆alquilo, -SO₂-C₃₋₈cicloalquilo, -SO₂NR⁶R⁷, -NH₂, -NH-CO-C₁₋₆alquilo, -NH-CO-C₃₋₈cicloalquilo, NH-CO-C₁₋₃alquilarilo, -NH-CO-C₁₋₃alquilheteroarilo, -NH-CO-arilo, -NH-CO-heteroarilo, -NHCO-heterocicloalquilo, -NH-CO-C₁₋₆alcoxi, -NH-COO-C₃₋₈cicloalquilo, -NH-COO-arilo, -NH-COO-heteroarilo, -NH-COO-heterocicloalquilo, -NH-COO-C₁₋₃alquilarilo, NHCONHR⁷, -NHCONR⁶R⁷, -NH-SO₂-C₁₋₈alquilo, -NH-SO₂-arilo, -NH-SO₂-heteroarilo y -NH-SO₂-C₃₋₈cicloalquilo; R³ se selecciona de hidrógeno, C₁₋₃alquilo, halo, CF₃ y C₁₋₃alcoxi; -L- es conector seleccionado de -SO₂- y -SO₂N(R⁵)-; el anillo A se selecciona de C₃₋₈cicloalquilo, arilo, heteroarilo y heterocicloalquilo; R⁴ se selecciona independientemente de hidrógeno, C₁₋₆alquilo, C₃₋₈cicloalquilo, -C₁₋₆alquilarilo, -C₁₋₆alquilheteroarilo, arilo, heteroarilo, heterocicloalquilo, halo, oxo, CN, CF₃, hidroxilo, -NO₂, -NH₂, C₁₋₆alcoxi, hidroxi-C₁₋₆alquilo, -S-C₁₋₆alquilo, -SO₂-C₁₋₆alquilo, -SO₂-C₃₋₈cicloalquilo, -SO₂-C₁₋₆alquilarilo, -SO₂-arilo, -SO₂-heteroarilo, -CO-C₁₋₆alquilo, -CO-C₁₋₆alquilarilo, -CO-C₃₋₈cicloalquilo, -CO-heterocicloalquilo, -CO-arilo, -CO-heteroarilo, C₁₋₆alcoxicarbonilo, -NR⁶R⁷, -NH-CO-C₁₋₆alquilo, -NH-CO-C₃₋₈cicloalquilo, -NH-CO-C₁₋₃alquilarilo, -NH-CO-C₁₋₃alquilheteroarilo, -NH-CO-arilo, -NH-CO-heteroarilo, -NH-CO-heterocicloalquilo, -NH-COO-C₁₋₆alquilo, -NH-COO-C₃₋₈cicloalquilo, -NH-COO-arilo, -NH-COO-heteroarilo, -NH-COO-heterocicloalquilo, -NH-COO-C₁₋₃alquilarilo, -NHCONR⁶R⁷, -NH-SO₂-C₁₋₆alquilo, -NH-SO₂-C₃₋₈cicloalquilo, -NH-SO₂-arilo, -NH-SO₂-heteroarilo, -C(O)OH, -C(O)OR⁶, -CONH₂, -CONH-arilo, -CONH-heteroarilo, -SO₂NH-C₁₋₈alquilo, -SO₂NH-C₃₋₈cicloalquilo y -SO₂NH-arilo donde los radicales arilo, heteroarilo y heterocicloalquilo están opcionalmente sustituidos por uno a cinco grupos seleccionados de -C₁₋₈alquilo, -C₃₋₇cicloalquilo, heterocicloalquilo, arilo, heteroarilo, C₁₋₆alcoxi, -O-arilo, halo, oxo, CN, -CF₃, -SO₂-C₁₋₈alquilo, -SO₂-arilo, -SO₂-heterocicloalquilo, -NH₂, -NR⁶R⁷, -NH-CO-C₁₋₈alquilo, -NH-SO₂-C₁₋₈alquilo, -NH-SO₂-arilo, -COOH, -C(O)NH-alquilo, -CONH-arilo, -CONH-heteroarilo, -C(O)-C₁₋₈alquilo, -C(O)O-C₁₋₈alquilo, -C(O)O-arilo, -SO₂NH-C₁₋₈alquilo, -SO₂NH-arilo, -SO₂NR⁶R⁷, -SO₂NH-heteroarilo y hidroxilo; R⁵ se selecciona de hidrógeno, C₁₋₆alquilo, aralquilo, C₃₋₈cicloalquilo y arilo; R⁶ y R⁷ se seleccionan independientemente de C₁₋₆alquilo, aralquilo, C₃₋₈cicloalquilo y arilo; o R⁶ y R⁷ tomados en conjunto podrán formar un anillo heterocicloalquilo; sus sales farmacéuticamente aceptables y sus isómeros, estereoisómeros, atropisómeros, confórmeros, tautómeros, polimorfos, hidratos o solvatos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621030183 | 2016-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109562A1 true AR109562A1 (es) | 2018-12-26 |
Family
ID=59955596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102438A AR109562A1 (es) | 2016-09-03 | 2017-09-01 | Compuestos de indazol como antagonistas de crth2 |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR109562A1 (es) |
| TW (1) | TW201819361A (es) |
| WO (1) | WO2018042377A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868376A1 (en) * | 2020-02-21 | 2021-08-25 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections |
| GB202108543D0 (en) * | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1448557A4 (en) | 2001-10-26 | 2005-02-02 | Univ Connecticut | HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS |
| WO2004022551A1 (ja) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | フランまたはチオフェン誘導体およびその医薬用途 |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| CA2589896A1 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| KR20100066422A (ko) | 2007-08-10 | 2010-06-17 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유사체 |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
| EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| JP5893155B2 (ja) * | 2011-11-17 | 2016-03-23 | 山▲東▼亨利医▲薬▼科技有限▲責▼任公司 | Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物 |
| AR096393A1 (es) | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
-
2017
- 2017-08-30 TW TW106129593A patent/TW201819361A/zh unknown
- 2017-09-01 WO PCT/IB2017/055261 patent/WO2018042377A1/en not_active Ceased
- 2017-09-01 AR ARP170102438A patent/AR109562A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201819361A (zh) | 2018-06-01 |
| WO2018042377A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| DOP2021000070A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| BR112021024131A2 (pt) | Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| MX382128B (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| AR099867A1 (es) | Compuestos imidazobenzotiazolo fusionados | |
| AR116036A1 (es) | DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6 | |
| AR109562A1 (es) | Compuestos de indazol como antagonistas de crth2 | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| MX376112B (es) | Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer. | |
| MX2017012943A (es) | Nuevos compuestos de piridinio. | |
| AR103254A1 (es) | Profármacos de creatina, composiciones y métodos de uso de estos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |